SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The sharp rally has no confirmed company-news catalyst; traders are focused on anticipation of the REGAL Phase 3 final analysis, which is triggered at 80 survival events after the last disclosed count of 78. Some interpret the CEOs anniversary message and SELLASs planned ASH presence as signs of a potential buyout, while others call that speculation and see the move as a rebound or possible short covering.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders watching guidance, subscriber engagement and advertising growth amid concerns about competition and a prolonged share-price decline. Many expect further weakness, while bulls argue pessimism is already priced in and see room for a rebound if results or the outlook are stronger than feared.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is drawing attention as traders position around the full Phase 3 melanoma results for its personalized cancer vaccine, intismeran, with Merck; the prior positive topline result has fueled a sharp rally. Bulls see validation of a broader oncology platform, while skeptics warn that expectations and valuation are stretched and debate a possible sell-the-news reaction.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound is being attributed by traders to possible short covering and anticipation of upcoming DM1 and FSHD siRNA data, with Arrowheads RNAi results cited as supportive context. No new Sarepta catalyst is confirmed in the discussion, and some traders view the move as technical or part of broader biotech strength.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff is being discussed amid broader neocloud concerns about financing, AI infrastructure spending returns, and whether providers can remain independent; traders also point to dilution and possible project delays. The community is split between bearish views that the weakness may persist and bullish arguments that IRENs cash-funded data centers and customer prepayments distinguish it from more debt-heavy peers.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings beat and new share-repurchase authorization are being overshadowed by a narrowed full-year profit outlook whose midpoint was unchanged, prompting a sharp selloff. Traders are split between viewing the buyback and stronger cash-flow outlook as support and seeing cautious guidance, lower U.S. sales, and cost pressures as reasons for the decline.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solanas volatile pullback and bounce amid broader crypto weakness are driving discussion, with traders watching support and Bitcoins direction. Dip-buyers are accumulating and staking, while bearish traders warn the recovery may fail and expect further downside.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA is drawing attention as it approaches and tests its 200-day moving average ahead of earnings, with traders watching for stronger volume and sustained momentum. Optimism about ASCENIV growth and share repurchases is tempered by calls for earnings to validate the outlook and lingering concerns over BIVIGAM weakness and management credibility.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal testing business to Labcorp is driving the sharp rally, with traders viewing the cash transaction as a potential balance-sheet and strategic reset. Bulls welcome the deal and momentum, while skeptics argue the sale removes a revenue-generating business and leaves concerns about declining operations and debt; the transaction remains subject to approval.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is drawing attention after a sharp post-earnings selloff despite beating expectations, as investors focused on slower U.S. da Vinci procedure growth and a cautious outlook. Traders are split between viewing the decline as an overreaction given the companys robotic-surgery position and recurring revenue, and seeing valuation, competition, and growth uncertainty as reasons for a reset.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares

Equity

Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.


Jordi Visser’s 20-Year Bombshell Prediction Includes ‘Religion, Gold, And Now Bitcoin’

Cryptocurrency

Visser said that crypto's real customer hasn't arrived yet, adding that "Crypto is not made for humans," naming AI agents as the real demand.


‘Pure Chartists Think It’s Over, I Don’t’ – Influential Macro Strategist Pushes Back On Bear Market Narrative

The Treasury General Account balance has declined, indicating that the government is bringing capital back into the markets, despite the tiny decline.


Bearish Sentiment

<ul class="summary-bullets"><li>Wood trimmed major recent winners, selling about $18 million of TWST along with smaller positions in TXG and CDNA.</li><li>RXRX has a 12-month consensus price target of $7.22, according to Koyfin, implying an upside potential of more than 51% from current levels.</li><li>Intellia is awaiting FDA review of its lead therapy for hereditary angioedema, with PDUFA date on March 10, 2027.</li></ul>Cathie Wood’s ARK Invest reshuffled its biotech holdings, buying several stocks that posted strong gains on Monday while trimming some of the sector’s biggest recent winners.Across&nbsp;<a href="https://stocktwits.com/symbol/ARKG">ARK Genomic Revolution ETF (ARKG)</a> and flagship&nbsp;<a href="https://stocktwits.com/symbol/ARKK">ARK Innovation ETF (ARKK)</a>, Wood bought about 1.48 million shares of Recursion Pharmaceuticals (RXRX), 96,308 shares of Intellia Therapeutics (NTLA), and 115,472 shares of Veracyte (VCYT), worth about $6.1 million, $1.2 million, and $5.3 million, respectively.Meanwhile, ARK sold 90,713 Twist Bioscience (TWST) shares worth $18 million, alongside smaller sales of 10x Genomics (TXG) and CareDx (CDNA).<h2 class="st-heading-2">What RXRX, NTLA And VCYT Have On Offer</h2><a href="https://stocktwits.com/symbol/RXRX">RXRX shares</a> surged more than 16% on Monday, and while there was no immediate trigger for the move, the AI drug-discovery company recently extended its data-licensing partnership with Tempus through 2029.The stock has a 12-month consensus price target of $7.22, according to Koyfin, implying an upside potential of more than 51% from current levels.<a href="https://stocktwits.com/symbol/NTLA">NTLA shares</a> closed 4% higher in the previous session, but the stock is currently down 2%. Intellia is awaiting U.S. Food and Drug Administration (FDA) review of its lead therapy for hereditary angioedema, with March 10, 2027, penciled in as the decision date.While NTLA shares have seen strong buying interest so far this year, surging more than 38%, Barclays believes the stock is likely to see a significant selloff. The firm initiated coverage with an ‘Underweight’ rating and an $8 price target, implying a 36% downside from current levels.Wood continued to build her <a href="https://stocktwits.com/symbol/VCYT">VCYT</a> position after adding roughly 159,000 shares earlier this month. Late last month, Veracyte said Phase 3 data showed its Decipher Prostate test could help identify which intermediate-risk prostate cancer patients may benefit from adding hormone therapy to radiation.According to Street estimates, the stock could climb at least 21% from current levels.&nbsp;&nbsp;<h2 class="st-heading-2">ARK Sells TWST, TXG, CDNA Despite Massive Moves</h2>ARK continued to unload <a class="mention" data-mention="$TWST" data-symbol-id="TWST" href="https://stocktwits.com/symbol/TWST" target="_blank">TWST shares</a> despite a sharp rally over the past month. TWST surged 8.7% on Monday and has added more than 60% to its value over the past month amid momentum around its synthetic-DNA platform and its agreement to support Eli Lilly’s TuneLab AI drug-discovery platform. Over the past few weeks, ARKG has unloaded TWST shares worth around $6 million.Meanwhile, TXG shares, which climbed 4.5% on Monday, have surged more than 48% in the past month, while <a href="https://stocktwits.com/symbol/CDNA">CDNA rose</a> 4% to its highest level in more than four years on Monday.<h2 class="st-heading-2">Retail’s Take On ARK’s Biotech Portfolio</h2>Retail sentiment on Stocktwits was bullish for TXG, NTLA, CDNA, and RXRX, bearish for VCYT, and neutral for TWST.<img src="https://news.stocktwits-cdn.com/ARK_YTD_8c95bdf841.png" alt="ARK YTD.png">Twist Bioscience and 10x Genomics have been the standout performers so far this year, up about 533% and 499%, respectively, while CareDx has gained roughly 265%, and NTLA, RXRX, and VCYT have posted double-digit advances.Also read:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/redwire-ceo-sees-massive-space-infrastructure-growth-ahead-compares-orbital-data-center-boom-to-rise-of-satellite-tv/cZDtb7wRBkY">Redwire CEO Sees ‘Massive’ Space Infrastructure Growth Ahead – Compares Orbital Data Center Boom To Rise Of Satellite TV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cathie Wood, CEO & Chief Investment Officer of ARK Invest, speaks onstage during Day 2 of 2023 Invest Fest at Georgia World Congress Center on August 27, 2023 in Atlanta, Georgia. (Photo by Paras Griffin/Getty Images)

Cathie Wood’s ARK Invest reshuffled its biotech holdings, buying several stocks that posted strong gains on Monday while trimming some of the sector’s biggest recent winners.

BlackRock Senior High Income Fund, Inc.

ARK Investment Management LLC - ARK Genomic Revolution ETF

Caredx Inc

Intellia Therapeutics Inc

Recursion Pharmaceuticals Inc

Twist Bioscience Corp

10x Genomics Inc - Ordinary Shares - Class A

Veracyte Inc

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Feed

News

Sentiment

Fundamentals

Info

ARK BlackRock Senior High Income Fund, Inc.

Latest ARK News